Results 231 to 240 of about 348,919 (331)

Efficacy and safety of tranexamic acid combined with low molecular weight heparin versus fondaparinux sodium following total knee arthroplasty: a retrospective cohort study. [PDF]

Front Pharmacol
Haibier A, Pan M, Anwar D, Ma P.
europepmc   +1 more source

Inflammatory Cytokines as Early Predictors of Weaning Failure From Extracorporeal Life Support

Artificial Organs, EarlyView.
Levels of IL‐8 and IL‐6 and their dynamics are reliable early predictors of ECLS weaning failure. ABSTRACT Background Weaning from extracorporeal life support (ECLS) in patients with refractory shock still remains a complex decision. Despite considerable advances in ECLS management, reliable biomarkers to predict weaning success are still not available.
Kostiantyn Kozakov, Alois Philipp, Maik Foltan, Anton Heller, Dzmitry Turtsevich, Christian Schach, Peter‐Paul Ellmauer, Walter Petermichl, Bernhard Flörchinger, Christof Schmid, Simon Schopka, Zdenek Provaznik   +11 more
wiley   +1 more source

Effect of Aspirin Versus Low-Molecular-Weight Heparin for Thromboprophylaxis in High-Risk and Fracture Location Subpopulations: A Secondary Analysis of the PREVENT CLOT Trial. [PDF]

J Orthop Trauma
Tarpada SP, O'Hara NN, Stein DM, DeSantis AJ, Castillo RC, Frey KP, Slobogean GP, Gitajn IL, Gaski GE, Kempton LB, Kleweno CP, Firoozabadi R, Cuschieri J, Christmas AB, Claridge JA, Marvel D, O'Toole RV, METRC.   +17 more
europepmc   +1 more source

The Impact of Obesity on Durable Left Ventricular Assist Device Implantation: A Systematic Review and Meta‐Analysis

Artificial Organs, EarlyView.
14 100 LVAD patients across 21 studies were analyzed. Findings indicated that obese LVAD recipients had lower short‐term mortality and higher risk of infection, thrombosis and right heart failure. There was no difference in long‐term survival between obese and non‐obese patients.
Hugh Jacobs, Olivia Frost, Arian Arjomandi Rad, Wing Kiu Chou, Sadeq Al‐Saegh, Alina Zubarevich, Alexander Weymann, Arjang Ruhparwar, Lukman Amanov, Peyman Sardari Nia, Antonios Kourliouros, Thanos Athanasiou   +11 more
wiley   +1 more source

Direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis in cancer-related surgeries: A meta-analysis of efficacy and safety outcomes. [PDF]

Am Heart J Plus
Mousavi A, Shojaei S, Dastjerdi P, Rahmati S, Izadpanahi K, Pishraft-Sabet H, Afshar EJ, Salehi K, Sabri M, Arbatan MN, Fallahtafti P, Wilbert A, Ambrosy AP, Syed MA, Iskander M, Hosseini K.   +15 more
europepmc   +1 more source

Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.

Blood, 2004
J. Gris, É. Mercier, I. Quéré, G. Lavigne-Lissalde, É. Cochery-Nouvellon, M. Hoffet, S. Ripart-Neveu, M. Tailland, M. Dauzat, P. Marés   +9 more
semanticscholar   +1 more source

Optimizing Prolonged (6 h) Normothermic Machine Perfusion of Donor Kidneys (PROPER Study)

Artificial Organs, EarlyView.
Prolonged ex situ normothermic machine perfusion of donor kidneys up to 6 h is feasible, maintaining viability and histological integrity. Key protocol optimizations include fresh red blood cells, albumin supplementation, and urine recirculation—laying the groundwork for assessment and potential pretransplant interventions in future clinical trials ...
Asel S. Arykbaeva, Veerle A. Lantinga, L. Leonie van Leeuwen, Marten Engelse, Ton J. Rabelink, Jesper Kers, Jason B. Doppenberg, Volkert A. L. Huurman, Robert A. Pol, Robert C. Minnee, Henri G. D. Leuvenink, Rutger J. Ploeg, Cyril Moers, Dorottya K. de Vries, Ian P. J. Alwayn   +14 more
wiley   +1 more source

Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study. [PDF]

Cancer Immunol Immunother
Zhang H, Li J, Yuan G, Huang S, Li X.
europepmc   +1 more source

Hemocompatibility and Long‐Term Outcomes in HeartWare Versus HeartMate II Versus HeartMate 3: Multicenter Real‐World Cohort

Artificial Organs, EarlyView.
Multicenter real‐world cohort (n = 327) comparing LVADs: HeartMate 3 (HM3), HeartMate II (HMII), and HeartWare (HVAD). HM3 showed superior long‐term survival versus legacy devices, driven by fewer hemocompatibility‐related adverse events, especially pump thrombosis and ischemic stroke, while major bleeding was similar across devices.
Hamza H. H. Ben Nasir, Ahmed F. A. Mohammed, Omar Allham, Alish Kolashov, Yusuf Shieba, Lachmandath Tewarie, Bernd Panholzer, Ajay Moza, Assad Haneya, Rashad Zayat   +9 more
wiley   +1 more source